GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals Life Sciences

More

  • SOUTH SAN FRANCISCO, Calif. _ Portola Pharmaceuticals Inc. on Tuesday reported a loss of $58.3 million in its second quarter. Portola Pharmaceuticals shares have increased 81 percent since the beginning of the year. Keywords: Portola Pharmaceuticals, Earnings Report.

  • WEST LAFAYETTE, Ind. _ Endocyte Inc. on Tuesday reported a second-quarter loss of $10.6 million, after reporting a profit in the same period a year earlier. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 30 cents per share. Endocyte shares have declined 17 percent since the beginning of the year.

  • Regeneron tops Street 2Q forecasts Tuesday, 4 Aug 2015 | 6:45 AM ET

    TARRYTOWN, N.Y. _ Regeneron Pharmaceuticals Inc. on Tuesday reported second-quarter profit of $194.6 million. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $2.68 per share. Nine analysts surveyed by Zacks expected $890.9 million.

  • Data from Thomson Reuters published on Tuesday showed the number of innovative medicines, or new molecular entities, launched globally in 2014 hit a 17- year high of 46, up from 29 in 2013.. Phase III terminations totalled 56 in the last three years, down from 68 in 2009-2011, according to the Thomson Reuters 2015 CMR Pharmaceutical R&D Factbook.

  • Array BioPharma reports 4Q loss Monday, 3 Aug 2015 | 8:18 AM ET

    BOULDER, Colo. _ Array BioPharma Inc. on Monday reported a loss of $12.7 million in its fiscal fourth quarter. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share. Array BioPharma shares have increased 23 percent since the beginning of the year.

  • *Worldwide cancer drug spending $100 billion in 2014. LONDON, Aug 3- New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. Pricey immunotherapies, offering long-lasting responses, are already starting to change...

  • LONDON, July 31- Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea. In the event, it proved about as safe as a flu vaccine, said University of Reading virologist Ben Neuman, but it was still not given to children or...

  • NewLink reports 2Q loss Friday, 31 Jul 2015 | 7:06 AM ET

    AMES, Iowa _ NewLink Genetics Corp. on Friday reported a loss of $14.1 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share. Three analysts surveyed by Zacks expected $5.6 million.

  • PTC Therapeutics reports 2Q loss Thursday, 30 Jul 2015 | 6:54 PM ET

    SOUTH PLAINFIELD, N.J. _ PTC Therapeutics Inc. on Thursday reported a loss of $38.4 million in its second quarter. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.20 per share. PTC Therapeutics shares have declined 2 percent since the beginning of the year.

  • Vivus reports 2Q loss Thursday, 30 Jul 2015 | 5:02 PM ET

    MOUNTAIN VIEW, Calif. _ Vivus Inc. on Thursday reported a loss of $49.4 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 23 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • Sunesis reports 2Q loss Thursday, 30 Jul 2015 | 7:45 AM ET

    SOUTH SAN FRANCISCO, Calif. _ Sunesis Pharmaceuticals Inc. on Thursday reported a loss of $8.9 million in its second quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share. Four analysts surveyed by Zacks expected $1.2 million.

  • Theravance reports 2Q loss Wednesday, 29 Jul 2015 | 7:10 PM ET

    SOUTH SAN FRANCISCO, Calif. _ Theravance Inc. on Wednesday reported a loss of $7.8 million in its second quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share. Theravance shares have risen 10 percent since the beginning of the year.

  • Vanda reports 2Q loss Wednesday, 29 Jul 2015 | 6:21 PM ET

    WASHINGTON _ Vanda Pharmaceuticals Inc. on Wednesday reported a loss of $5.4 million in its second quarter. The Washington- based company said it had a loss of 13 cents per share. Keywords: Vanda Pharmaceuticals, Earnings Report.

  • Corium reports 3Q loss Wednesday, 29 Jul 2015 | 6:15 PM ET

    MENLO PARK, Calif. _ Corium International Inc. on Wednesday reported a loss of $5.9 million in its fiscal third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 37 cents per share. Three analysts surveyed by Zacks expected $10.5 million.

  • Dyax reports 2Q loss Wednesday, 29 Jul 2015 | 5:45 PM ET

    BURLINGTON, Mass. _ Dyax Corp. on Wednesday reported a loss of $8.4 million in its second quarter. Dyax shares have risen 73 percent since the beginning of the year. Access a Zacks stock report on DYAX at http://www.zacks.com/ap/DYAX.

  • Cytokinetics reports 2Q loss Wednesday, 29 Jul 2015 | 5:24 PM ET

    SOUTH SAN FRANCISCO, Calif. _ Cytokinetics Inc. on Wednesday reported a loss of $10.6 million in its second quarter. On a per-share basis, the South San Francisco, California- based company said it had a loss of 27 cents. Cytokinetics shares have dropped 12 percent since the beginning of the year.

  • LONDON, July 29- British investor Neil Woodford is backing a start-up biopharmaceutical firm whose first venture will be to launch clinical trials of three drugs developed by Novartis. It said has raised $119 million from Woodford Investment and Invesco Perpetual among others, and has acquired drug programmes from Novartis for the treatment of brittle bone...

  • LONDON, July 28- Researchers in the United States trying to develop a vaccine against the deadly Middle East Respiratory Syndrome virus say they have had early signs of success in animal experiments. MERS, which causes coughing and fever and can lead to fatal pneumonia and kidney failure, has been reported mainly in Saudi Arabia and South Korea but has also been...

  • How effective is new malaria vaccine? Friday, 24 Jul 2015 | 11:40 AM ET
    How effective is new malaria vaccine?

    Suki Virji, analyst for Scrip Intelligence, discusses the malaria vaccine developed by GlaxoSmithKline, which has received a "green light" by the European Medicines Agency.

  • LONDON, July 24- AstraZeneca is dipping its toe in the biosimilars market, as a way to make future cancer drug cocktails more affordable, by linking with a Japanese group to develop a copy of Roche's blockbuster medicine Avastin. FKB-- itself a tie-up between Fujifilm and Kyowa Hakko Kirin-- commenced a Phase I clinical trial of its copy of Avastin, called FKB238, in...